Trial reportCritical care medicine2010
Plasma interleukin-8 is not an effective risk stratification tool for adults with vasopressor-dependent septic shock.
Trial report in Critical care medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- Cytokine-based strategies to improve prognostic enrichment of pediatric ARDS.Critical care (London, England) · 2026Observational
- A prospective investigation of interleukin-8 levels in pediatric acute respiratory failure and acute respiratory distress syndrome.Critical care (London, England) · 2019Article
- Sepsis Biomarkers.Journal of pediatric intensive care · 2019Review
- Adaptation of a Biomarker-Based Sepsis Mortality Risk Stratification Tool for Pediatric Acute Respiratory Distress Syndrome.Critical care medicine · 2018Observational
- Patient Characteristics, Management, and Predictors of Outcome from Severe Community-Onset Staphylococcal Sepsis in Northeast Thailand: A Prospective Multicenter Study.The American journal of tropical medicine and hygiene · 2017Observational
- Cytokine Profiles of Severe Influenza Virus-Related Complications in Children.Frontiers in immunology · 2017Article
- Emerging infection and sepsis biomarkers: will they change current therapies?Expert review of anti-infective therapy · 2016Review
- Diagnosing sepsis - The role of laboratory medicine.Clinica chimica acta; international journal of clinical chemistry · 2016Review
- Performance of interleukin-27 as a sepsis diagnostic biomarker in critically ill adults.Journal of critical care · 2014Article
- The pediatric sepsis biomarker risk model: potential implications for sepsis therapy and biology.Expert review of anti-infective therapy · 2014Review
- Gene expression profiling in sepsis: timing, tissue, and translational considerations.Trends in molecular medicine · 2014Review
- Biomarkers for sepsis: a review with special attention to India.BioMed research international · 2014Review
- Role of biomarkers in sepsis care.Shock (Augusta, Ga.) · 2013Review
- Genome-wide expression profiling in pediatric septic shock.Pediatric research · 2013Review
- New approaches to sepsis: molecular diagnostics and biomarkers.Clinical microbiology reviews · 2012Article
- Genetics and genomics in pediatric septic shock.Critical care medicine · 2012Review
- Clinical review: sepsis and septic shock--the potential of gene arrays.Critical care (London, England) · 2012Review
- Biomarkers in acute lung injury: insights into the pathogenesis of acute lung injury.Critical care clinics · 2011Review
- Finding new therapies for sepsis: the need for patient stratification and the use of genetic biomarkers.Critical care (London, England) · 2011Article
- Biomarkers for pediatric sepsis and septic shock.Expert review of anti-infective therapy · 2011Review
Corrections and comments
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
objectivePlasma interleukin-8 levels of <220 pg/mL have an excellent negative predictive value (94% to 95%) for death at 28 days in children with septic shock and thus may be useful for risk stratification in clinical trial enrollment in this population. Whether plasma interleukin-8 would have similar utility in adults with septic shock is unknown.
designAnalysis of plasma interleukin-8 levels and prospectively collected clinical data from patients enrolled in two large randomized controlled trials of ventilator strategy for acute lung injury.
settingIntensive care units of university hospitals participating in the National Institutes of Health Acute Respiratory Distress Syndrome Network. PATIENTS: One hundred ninety-two adult patients with vasopressor-dependent septic shock.
interventionsNone. MEASUREMENTS AND MAIN
resultsPlasma interleukin-8 levels > or =220 pg/mL were significantly associated with death at 28 days in this cohort (odds ratio, 2.92; 95% confidence interval, 1.42 to 5.99; p = .001). However, in contrast to the findings in pediatric septic shock, a plasma interleukin-8 cutoff <220 pg/mL had a negative predictive value for death of only 74% (95% confidence interval, 66% to 81%) in adults with septic shock. Receiver operating characteristic analysis found an area under the curve of 0.59 for plasma interleukin-8, indicating that plasma interleukin-8 is a poor predictor of mortality in this group. In adults aged <40 yrs, a plasma interleukin-8 cutoff <220 pg/mL had a negative predictive value of 92%.
conclusionsIn contrast to similar pediatric patients, plasma interleukin-8 levels are not an effective risk stratification tool in older adults with septic shock. Future studies of biomarkers for risk stratification in critically ill subjects will need to be replicated in multiple different populations before being applied in screening for clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.